Pharmacoeconomic and Pharmaceutical Management Department, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences-Islamic Azad University, Tehran, Iran.
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, No 10, Jalale-Al-Ahmad Ave, Chamran Highway, Tehran, 1411713137, Iran.
BMC Health Serv Res. 2022 Feb 2;22(1):137. doi: 10.1186/s12913-022-07551-z.
Due to the high and increasing economic burden of chronic diseases, including Multiple sclerosis (MS), we aimed to investigate the medical cost of MS in Iran.
This is a descriptive cross-sectional study which conducted using comprehensive national prescription data from Iran's Health Insurance Organization (IHIO) and rehabilitation data from Ministry of Health and Iran Welfare Organization. The time period considered for this study was 2019-2020. In order to calculate the medical cost of MS, the cost-of-illness (COI) method was used based on the prevalence-based approach and the cost of medications, determining and diagnosing the MS risk, follow-up and rehabilitation was estimated.
The total medical cost of MS in Iran in 2019-2020 was estimated at $238,124,160, which medications and rehabilitation services had the largest share in the medical cost of MS in Iran with 80 and 19%, respectively, and the cost share of determining and diagnosing of the disease risk accounted for about less than 1%. The total medication cost was estimated to be equal to $192,298 thousand. The total cost of determining and diagnosing of the MS risk was estimated at $348,574 and the total cost of rehabilitation services for all MS subgroups in 2019-2020 was estimated at $45,477,205.
Results of calculating the medical cost of MS in Iran in 2019-2020 showed a significant burden on the Iranian health care system and society, among which the medication cost had the largest share, which requires serious attention of health system policymakers.
由于包括多发性硬化症（MS）在内的慢性病的经济负担高且不断增加，我们旨在研究伊朗的 MS 医疗费用。
这是一项描述性的横断面研究，使用了伊朗健康保险组织（IHIO）的综合国家处方数据和卫生部和伊朗福利组织的康复数据进行。这项研究的时间范围是 2019-2020 年。为了计算 MS 的医疗费用，采用了基于患病率的方法和药物成本的疾病成本法（COI），估计了 MS 风险的确定和诊断、随访和康复的成本。
2019-2020 年，伊朗 MS 的总医疗费用估计为 23812.416 万美元，其中药物和康复服务在伊朗 MS 医疗费用中占比最大，分别为 80%和 19%，而疾病风险的确定和诊断的成本占比约为 1%。总药物费用估计为 1922.98 万美元。MS 风险确定和诊断的总成本估计为 348574 美元，2019-2020 年所有 MS 亚组的康复服务总成本估计为 45477205 美元。
计算 2019-2020 年伊朗 MS 医疗费用的结果表明，伊朗的医疗保健系统和社会负担沉重，其中药物费用占比最大，这需要卫生系统政策制定者的高度关注。
